Nose-to-brain delivery possible but challenges remain

Nose-to-brain delivery can become a reality, even for molecules with high molecular weights, but barriers relating to administration and adsorption remain, according to a panel at AAPS.

Links between the nose and the limbic system makes intranasal delivery a potential route for drugs to reach the central nervous system (CNS). However, so far most research has used rats, which have very different noses to humans, and doubts remain over delivering macromolecules.

These concerns were addressed by researchers at an AAPS Sunrise Session, entitled “Nose to Brain Delivery: Reality or Just Blowing Smoke?” Speaking at the session, Lisbeth Illum, CEO of Critical Pharmaceuticals, outlined the known nose-to-brain routes and barriers to adoption.

Illum said the three main challenges are: efficiently targeting the olfactory region, which is one of the three routes from nose-to-brain, the others being systemic and via the trigeminal nerve; retaining formulations in the olfactory region; and enhancing adsorption.

To efficiently target the olfactory region Illum believes novel nasal drug delivery devices will be needed. Another speaker at the session, Per Djupesland, chief scientific officer at OptiNose, gave a presentation on a device which is being developed to meet this need.

Djupesland said the human nose, and in particular the nasal valve, makes it difficult to deliver a therapeutic to the critical sites. To address these issues OptiNose has developed a breath actuated delivery device which it claims can target the olfactory region without lung deposition.

Studies suggest the device is capable of nose-to-brain delivery, said Djupesland, but it is much harder to validate this in humans than rats, largely because rats can be sacrificed to view the brain.

Macromolecules

In the other presentation Shyeilla Dhuria, a senior scientist at Novartis, showed research that delivered growth differentiation factor 5 (GDF-5), a molecule with a high molecular weight, to the mid-brain in rats.

Delivery to the mid-brain was achieved using a lipid nanosphere (LNS) formulation of GDF-5. Dhuria said use of LNS increased delivery to the mid-brain and other formulations could be used to target different pathways.

This would allow researchers to target different areas of the brain. For instance, the olfactory route of delivery is believed to reach the front of the brain, whereas the trigeminal nerve primarily administers drugs to the back of the brain.

Since CNS diseases often affect specific regions of the brain, for instance Pick’s disease often begins in the frontal lobe, the ability to target these regions could increase efficacy while decreasing side effects.

In light of this and other research Dhuria believes nose-to-brain delivery can become a reality. However, for it to succeed potent drugs with high solubility need to be found.

Related News

Novartis to reduce US sales force, days after denying job cut rumours

OptiNose OKed for Phase III trial of nasal delivery tech

OptiNose OKed for Phase III trial of nasal delivery tech

in-Pharmatechnologist looks at the latest news in drug delivery

Levitra, Herceptin combo used to target brain metastases

Terapio lands $5m to develop delivery tech

Genzyme targets BBB

Versatile BBB drug delivery tech appears safe

'Trojan horse' crosses blood-brain barrier

Related Products

See more related products

Comments (2)

Nick Taylor - 29 Nov 2010 | 09:49

@kushal

Thanks Kushal - glad to hear you enjoyed the article.

29-Nov-2010 at 09:49 GMT

kushal - 27 Nov 2010 | 09:04

thanks

dear Nick thanks for sharing this informative and interesting session.

27-Nov-2010 at 21:04 GMT

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.